Implementation of our pathology-supported genetic testing (PSGT) strategy will enable BRCA1/2 screening in BC patients unselected by age or family history through integration of germline DNA testing with tumor gene profiling, as envisaged for future application of pharmacogenomics in Africa. The gene discussed is BRCA1; the disease is breast cancer.